Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preoperative cardiovascular evaluation in patients with cancer.

Frontiers in cardiovascular medicine·2026
Same author

QT monitoring in chemotherapy.

Frontiers in cardiovascular medicine·2026
Same author

Onco-hypertension: hypertension induced by VEGF pathway inhibition.

Frontiers in cardiovascular medicine·2026
Same author

Ionizing radiation expands a p90RSK-activated patrolling monocyte subset: modulation by colchicine.

Frontiers in cardiovascular medicine·2026
Same author

SHP2: A Redox-Sensitive Regulator Linking Immune Checkpoint Inhibitor Therapy to Cancer Treatment and Vascular Risk.

Antioxidants (Basel, Switzerland)·2025
Same author

Pulmonary artery pressure via endobronchial ultrasound: A feasibility and safety study.

JTCVS techniques·2025

Related Experiment Video

Updated: Jun 2, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Chemotherapy-induced cardiomyopathy.

Syed Wamique Yusuf1, Nasreen A Ilias-Khan, Jean-Bernard Durand

  • 1University of Texas MD Anderson Cancer Center, Department of Cardiology, 1515 Holcombe Blvd, Unit 1451, Houston, TX 77030, USA. syusuf@mdanderson.org

Expert Review of Cardiovascular Therapy
|April 21, 2011
PubMed
Summary
This summary is machine-generated.

Cancer survivors may develop chemotherapy-induced cardiomyopathy years after treatment. Early recognition and treatment are crucial for potential recovery of cardiac function.

More Related Videos

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

Related Experiment Videos

Last Updated: Jun 2, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

Area of Science:

  • Cardiology
  • Oncology
  • Pharmacology

Background:

  • Cancer therapies, particularly chemotherapy, can cause long-term cardiotoxic effects.
  • Chemotherapy-induced cardiomyopathy is a growing concern in cancer survivorship.
  • Cardiac dysfunction may manifest years after treatment completion.

Purpose of the Study:

  • To review the mechanisms and clinical presentation of chemotherapy-induced cardiomyopathy.
  • To discuss the diagnostic approaches for early detection.
  • To outline current and emerging treatment strategies.

Main Methods:

  • Literature review of studies on chemotherapy-induced cardiomyopathy.
  • Analysis of clinical data regarding long-term cardiac effects of chemotherapy.
  • Synthesis of information on management and treatment options.

Main Results:

  • Chemotherapy can lead to significant cardiac impairment, including cardiomyopathy.
  • Early identification of cardiotoxicity is associated with better outcomes.
  • Treatment strategies aim to mitigate cardiac damage and improve function.

Conclusions:

  • Chemotherapy-induced cardiomyopathy is a serious, yet often manageable, late effect of cancer treatment.
  • Prompt diagnosis and intervention can preserve or restore cardiac function in survivors.
  • Ongoing research is vital for improving prevention and treatment protocols.